| ［1］Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas: a systematic review［J］. Cancer,2004,101(3):613-619.［2］Asa SL, Ezzat S. The pathogenesis of pituitary tumours［J］. Nat Rev Cancer,2002,2(11):836-849.［3］Lania A, Spada A. G-protein and signalling in pituitary tumours［J］. Horm Res,2009,71（Suppl 2）:95-100.［4］Lania A, Mantovani G, Spada A. Genetics of pituitary tumors: focus on G-protein mutations［J］.Exp Biol Med (Maywood),2003,228(9):1004-1017.［5］Lin Y, Jiang XF, Shen Y, et al. Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors［J］. Endocr Relat Cancer,2009,16(1):301-310.［6］Pei L, Melmed S. Isolation and characterization of a pituitary tumor-transforming gene (PTTG)［J］. Mol Endocrinol, 1997,11(4):433-441.［7］Salehi F, Kovacs K, Scheithauer BW, et al. Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update［J］. Endocr Relat Cancer,2008,15(3):721-743.［8］Tong Y, Tan Y, Zhou C, et al. Pituitary tumor transforming gene interacts with Sp1 to modulate G1/S cell phase transition［J］. Oncogene,2007,26(38):5596-5605. ［9］Chesnokova V, Zonis S, Rubinek T, et al. Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth［J］. Cancer Res,2007,67(21):10564-10572.［10］Filippella M, Galland F, Kujas M, et al. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study［J］. Clin Endocrinol (Oxf),2006,65(4):536-543. ［11］Abbud RA, Takumi I, Barker EM, et al. Early multipotential pituitary focal hyperplasia in the alpha-subunit of glycoprotein hormone-driven pituitary tumor-transforming gene transgenic mice［J］. Mol Endocrinol,2005,19(5):1383-1391.［12］Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia type 1［J］. Science,1997,276(5311):404-407.［13］Agarwal SK, Ozawa A, Mateo CM, et al. The MEN1 gene and pituitary tumours［J］. Horm Res,2009,71(Suppl 2):131-138.［14］Cazabat L, Guillaud-Bataille M, Bertherat J, et al. Mutations of the gene for the aryl hydrocarbon receptor-interacting protein in pituitary adenomas［J］. Horm Res,2009,71(3):132-141.［15］Leontiou CA, Gueorguiev M, van der Spuy J, et al. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas［J］. J Clin Endocrinol Metab, 2008,93(6):2390-2401.［16］Vierimaa O, Georgitsi M, Lehtonen R, et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene［J］. Science,2006,312(5777):1228-1230.［17］Kirschner LS. PRKAR1A and the evolution of pituitary tumors［J］.Mol Cell Endocrinol,2010,326(1-2):3-7.［18］Yin Z, Williams-Simons L, Parlow AF, et al. Pituitary- specific knockout of the Carney complex gene prkar1a leads to pituitary tumorigenesis［J］. Mol Endocrinol,2008,22(2):380-387.［19］Karhu A, Aaltonen LA. Susceptibility to pituitary neoplasia related to MEN-1, CDKN1B and AIP mutations: an update［J］.Hum Mol Genet,2007,16(1):R73-R79.［20］Marinoni I, Pellegata NS. p27kip1: a new multiple endocrine neoplasia gene ［J］.Neuroendocrinology,2011,93(1):19-28.［21］Matoso A, Zhou Z, Hayama R, et al. Cell lineage-specific interactions between Men1 and Rb in neuroendocrine neoplasia［J］.Carcinogenesis,2008,29(3):620-628.［22］Chesnokova V, Zonis S, Kovacs K, et al. p21Cip1 restrains pituitary tumor growth［J］. Proc Natl Acad Sci USA,2008, 105(45):17498-17503.［23］Zhang X, Sun H, Danila DC, et al. Loss of expression of GADD45γ, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis［J］.J Clin Endocrinol Metab,2002,87(4):1262-1267.［24］Zhao J, Dahle D, Zhou Y, et al. Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors［J］.J Clin Endocrinol Metab,2005,90(4):2179-2186.［25］Dworakowska D, Grossman AB. The pathophysiology of pituitary adenomas［J］. Best Pract Res Clin Endocrinol Metab,2009,23(5):525- 541.［26］Asa SL, Ezzat S. The pathogenesis of pituitary tumors［J］. Annu Rev Pathol,2009,4(4):97-126.［27］Ezzat S, Zheng L, Asa SL. Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia［J］. Mol Endocrinol,2004,18(10):2543-2552.［28］Ezzat S, Yu S, Asa SL. The zinc finger Ikaros transcription factor regulates pituitary growth hormone and prolactin gene expression through distinct effects on chromatin accessibility［J］. Mol Endocrinol,2005,19(4):1004-1011.［29］Ezzat S, Asa SL. The emerging role of the Ikaros stem cell factor in the neuroendocrine system［J］.J Mol Endocrinol,2008, 41(2):45-51. ［30］Cakir M, Grossman AB. Targeting MAPK (Ras/ERK) and PI3K/Akt pathways in pituitary tumorigenesis［J］. Expert Opin Ther Targets,2009,13(9):1121-1134.［31］Dworakowska D, Wlodek E, Leontiou CA, et al. Activation of Raf/MEK/ERK and PI3K/Akt/mTOR pathways in pituitary adenomas and their effects on downstream effectors［J］. Endocrine Related Cancer,2009,16(4):1329-1338. |
Acta Academiae Medicinae Sinica
